Zobrazeno 1 - 10
of 132
pro vyhledávání: '"E Michael Ostap"'
Autor:
Aaron Snoberger, Bipasha Barua, Jennifer L Atherton, Henry Shuman, Eva Forgacs, Yale E Goldman, Donald A Winkelmann, E Michael Ostap
Publikováno v:
eLife, Vol 10 (2021)
Hypertrophic cardiomyopathies (HCMs) are the leading cause of acute cardiac failure in young individuals. Over 300 mutations throughout β-cardiac myosin, including in the motor domain, are associated with HCM. A β-cardiac myosin motor mutation (R71
Externí odkaz:
https://doaj.org/article/a7523ab1d3fc41fc9e768c62b8590538
Publikováno v:
eLife, Vol 8 (2019)
Key steps of cardiac mechanochemistry, including the force-generating working stroke and the release of phosphate (Pi), occur rapidly after myosin-actin attachment. An ultra-high-speed optical trap enabled direct observation of the timing and amplitu
Externí odkaz:
https://doaj.org/article/7e6497584f8c4b5f9f10fe21aaa0176a
Autor:
Stephen M. Coscia, Andrew S. Moore, Cameron P. Thompson, Christian F. Tirrito, E. Michael Ostap, Erika L. F. Holzbaur
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-15 (2024)
Abstract Across the cell cycle, mitochondrial dynamics are regulated by a cycling wave of actin polymerization/depolymerization. In metaphase, this wave induces actin comet tails on mitochondria that propel these organelles to drive spatial mixing, r
Externí odkaz:
https://doaj.org/article/b4f6bb7cc21d4868bbb681cbfdfcfe3d
Publikováno v:
PLoS ONE, Vol 7, Iss 8, p e43662 (2012)
In adipocytes, vesicles containing glucose transporter-4 (GLUT4) redistribute from intracellular stores to the cell periphery in response to insulin stimulation. Vesicles then fuse with the plasma membrane, facilitating glucose transport into the cel
Externí odkaz:
https://doaj.org/article/ead972cd8de84dd4ba91e1a77d8fd8aa
Publikováno v:
The Journal of Clinical Investigation, Vol 132, Iss 5 (2022)
Myosin modulators are a novel class of pharmaceutical agents that are being developed to treat patients with a range of cardiomyopathies. The therapeutic goal of these drugs is to target cardiac myosins directly to modulate contractility and cardiac
Externí odkaz:
https://doaj.org/article/22af51a26563487ba7b553835dc6fafb
Autor:
Michael S. Woody, Michael J. Greenberg, Bipasha Barua, Donald A. Winkelmann, Yale E. Goldman, E. Michael Ostap
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-11 (2018)
Omecamtiv mecarbil (OM) is a positive cardiac inotrope in clinical trials for the treatment of heart failure whose mechanism of action is incompletely understood. Here the authors show that OM inhibits myosin's working stroke and prolongs actomyosin
Externí odkaz:
https://doaj.org/article/a390d9a0840145559f69f13c5f0635e6
Autor:
Ross TA Pedersen, Aaron Snoberger, Serapion Pyrpassopoulos, Daniel Safer, David G Drubin, E Michael Ostap
SummaryPedersen, Snoberger et al. measure the force-sensitivity of the yeast endocytic the myosin-1 called Myo5 and find that it is more likely to generate power than to serve as a force-sensitive anchor in cells. Implications for Myo5’s role in cl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bb196c116c5dc09df583b0f44d9e328d
https://doi.org/10.1101/2023.03.21.533689
https://doi.org/10.1101/2023.03.21.533689
Autor:
Stephen M. Coscia, Cameron P. Thompson, Qing Tang, Elana E. Baltrusaitis, Joseph A. Rhodenhiser, Omar A. Quintero-Carmona, E. Michael Ostap, Melike Lakadamyali, Erika L. F. Holzbaur
Publikováno v:
Journal of Cell Science. 136
Mitochondrial homeostasis requires a dynamic balance of fission and fusion. The actin cytoskeleton promotes fission, and we found that the mitochondrially localized myosin, myosin 19 (Myo19), is integral to this process. Myo19 knockdown induced mitoc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ceff89ddaa9b226a36cb5b5f81af771c
https://doi.org/10.1242/jcs.260612
https://doi.org/10.1242/jcs.260612
Autor:
Serapion Pyrpassopoulos, Allison M. Gicking, Taylor M. Zaniewski, William O. Hancock, E. Michael Ostap
Publikováno v:
Proceedings of the National Academy of Sciences. 120
KIF1A is a highly processive vesicle transport motor in the kinesin-3 family. Mutations in KIF1A lead to neurodegenerative diseases including hereditary spastic paraplegia. We applied optical tweezers to study the ability of KIF1A to generate and sus
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::579b649e0bb6d9e53bd87a3e60e0d418
https://doi.org/10.1073/pnas.2216903120
https://doi.org/10.1073/pnas.2216903120
Autor:
Serapion Pyrpassopoulos, Allison M. Gicking, Taylor M. Zaniewski, William O. Hancock, E. Michael Ostap
KIF1A is a highly processive vesicle transport motor in the kinesin-3 family. Mutations in KIF1A lead to neurodegenerative diseases including hereditary spastic paraplegia. We applied optical tweezers to study the ability of KIF1A to generate and sus
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::132978ecf03e8d7aae885d9b3c0239f7
https://doi.org/10.1101/2022.05.16.492183
https://doi.org/10.1101/2022.05.16.492183